Chefs' Warehouse Inc
Change company Symbol lookup
Select an option...
CHEF Chefs' Warehouse Inc
FRBA FIRST BANK (Hamilton)
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MMM 3M Co
MPX Marine Products Corp
Go

Consumer Staples : Food & Staples Retailing | Small Cap Blend
Company profile

The Chefs' Warehouse, Inc. is a distributor of specialty food products in the United States and Canada. The Company operates through food product distribution segment, which is concentrated on the East and West Coasts of the United States. The Company is focused on serving the specific needs of chefs owning and/or operating some of the menu-driven independent restaurants, fine dining establishments, Country clubs, hotels, caterers, culinary schools, bakeries, patisseries, chocolatiers, cruise lines, casinos and specialty food stores in the United States and Canada. Its product portfolio consists of imported and domestic specialty food products, such as artisan charcuterie, specialty cheeses, oils and vinegars, truffles, caviar, chocolate and pastry products. The Company also offers a line of center-of-the-plate products, including custom cut beef, seafood and hormone-free poultry, as well as food products, such as cooking oils, butter, eggs, milk and flour.

Price
Delayed
$12.86
Day's Change
-2.71 (-17.41%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.13
Day's Low
12.82
Volume
(Heavy Day)

Today's volume of 863,409 shares is on pace to be much greater than CHEF's 10-day average volume of 541,404 shares.

863,409

Medtronic Gets Affirmation of Key Sacral Neuromodulation Patent

1:35 pm ET September 25, 2020 (PR Newswire) Print

Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim(TM) systems. The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office rejected in its entirety Axonics' attempt to invalidate a key Medtronic patent.

"Medtronic is pleased with the PTAB's decision to uphold the most important of the patents challenged," said Brooke Story, vice president and general manager of Medtronic's Pelvic Health & Gastric Therapies business, which is part of the Restorative Therapies Group. "Innovation is vital to our business and we will vigorously defend our IP Portfolio in this case."

Medtronic filed suit against Axonics in November 2019, asserting claims for infringement of seven patents. In response, Axonics filed Inter Partes Review (IPR) on all seven patents. However, the PTAB has now rejected without hearing the challenge to Medtronic's U.S. Patent No. 9,463,324 ('324 patent) and found that Axonics' arguments lack merit. The '324 patent protects key technology related to implant recharging and temperature control and is central to the infringement case pending against Axonics. In rejecting Axonics' arguments, the PTAB found there was no reasonable likelihood that any claims of the '324 patent are invalid. That decision by the PTAB is final and not appealable.

Over the last week, the PTAB has also decided to institute full IPR proceedings related to the six additional patents at issue. In those IPR proceedings, the PTAB will hear testimony and argument from both sides.

"Contrary to Axonics' assertions, the PTAB has not made any final determination that any of Medtronic's patent claims are invalid," said Story. "The full IPR process will begin now, and the PTAB will issue a decision within the next 12 months."

Medtronic has the world's smallest rechargeable bladder/bowel control system and the fastest battery recharge available and is the only company that offers patients the choice of a rechargeable or recharge-free sacral neuromodulation device. With 25-years' experience of innovation, investment and pioneering therapy, Medtronic is the only company with five-year data across four indications demonstrating the safety and efficacy of its sacral neuromodulation systems.

About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Katie Genereux   Ryan Weispfenning
Public Relations Investor Relations
+1-763-514-0162  +1-763-505-4626

https://mma.prnewswire.com/media/1246632/Medtronic_Logo.jpg

https://c212.net/c/img/favicon.png?sn=CG37250&sd=2020-09-25

View original content to download multimedia:http://www.prnewswire.com/news-releases/medtronic-gets-affirmation-of-key-sacral-neuromodulation-patent-301138320.html

SOURCE Medtronic plc

https://rt.prnewswire.com/rt.gif?NewsItemId=CG37250&Transmission_Id=202009251335PR_NEWS_USPR_____CG37250&DateId=20200925

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.